Clinical Trial Update: SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations [Phase 3]

View source ↗

Summary

A Phase 3 trial (SELVA) is evaluating QTORIN 3.9% Rapamycin Anhydrous Gel for microcystic lymphatic malformation, and the study is currently active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microcystic Lymphatic Malformation

Drugs mentioned

• QTORIN 3.9% Rapamycin Anhydrous Gel (Rapamycin)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Microcystic Lymphatic Malformation | Phase 3 | Status: ACTIVE_NOT_RECRUITING